Patients suffering from opioid use disorder often relapse during periods of abstinence, which is posited to be caused by negative reinforcement driving motivated behaviors. Here, we explored whether opioid-seeking behaviors in mice were correlated with the negative affect of anxiety. To do this, we conditioned mice to associate a specific context with morphine, an opioid with strongly addictive properties, using a three compartment chamber. 24 h following five days of morphine (10 mg/kg, i.p.) conditioning, anxiety levels were tested by measuring time in the open arms of an elevated plus maze. The next day, mice were placed in the three compartment chamber to measure morphine-induced conditioned place preference (CPP). Our results show that following morphine conditioning, mice spent significantly less time in the open arm of the elevated plus maze, which was negatively correlated with the CPP score. Furthermore, we found that an acute treatment with (R,S)-ketamine (10 mg/kg, i.p.), a medication demonstrating promise for preventing anxiety-related phenotypes, 30 min. prior to testing on post conditioning day 1, increased time spent in the open arm of the elevated plus maze in morphine conditioned mice. Lastly, we found that a second injection of ketamine 30 min. prior to CPP tests on post conditioning day 2 attenuated morphine-induced CPP, which lasted for up to 28 d. Overall, our results suggest that morphine-induced CPP may be driven by negative reinforcement, which can be prevented by acute ketamine administration.
Introduction 1
Ketamine is a potent noncompetitive antagonist at the N-methyl-D-aspartate (NMDA) receptor 2 (Ebert et al., 1997) and is approved by the Food and Drug Administration as a general anesthetic 3 in humans. Ketamine also is used off label for analgesia (Quibell et al., 2011), complex regional Our results show that the percent time spent in the open arms of the elevated plus maze is 156 decreased in animals conditioned with morphine. Additionally, we show a significant correlation 157 between anxiety-like behaviors and morphine CPP such that decreases in the time spent in the 158 open arms of the elevated plus maze (increased anxiety-like behavior) is correlated with 159 increases in the time spent in the morphine-paired context. Lastly, we show that an acute 160 injection of (R,S)-ketamine 30 min prior to the elevated plus maze and CPP tests is sufficient to 161 block morphine-induced anxiety-like behaviors and morphine-induced CPP on post-conditioning 162 day 1 and up to 28 d post conditioning. 163 Anxiety-like behaviors during morphine abstinence 164 Morphine possesses anxiolytic-like properties during initial exposure (Koks et al., 1999; Sasaki et 165 al., 2002; Shin et al., 2003) . However, during opioid abstinence, symptoms of anxiety (Gold et 166 al., 1978; 1979; Li et al., 2009; Shi et al., 2009) or anxiety-like behaviors are observed (Cabral et 167 al., 2009; Becker et al., 2017) . Here, we show that 24 h following repeated morphine injections 168 (once a day for 5 days), mice display anxiety-like behaviors in the elevated plus maze (Fig. 1C) . 169 These results are similar to previous studies showing escalating doses of morphine over a 6 day 170 period induce anxiety-like behaviors in the marble burying task (Becker et al., 2017) .
171
Additionally, our observed morphine-induced anxiety-like behavior is timed with anxiogenic 172 neurobiological responses that occur during acute opioid abstinence including, increases in 173 norepinephrine release in the extended amygdala (Fuentealba et al., 2000) , norepinephrine-174 induced modulation of the extended amygdala (Aston-Jones et al., 1999; Delfs et al., 2000; Smith 175 and Aston-Jones, 2008), activation of the amygdalar corticotrophin-releasing factor (CRF) 176 system (Heinrichs et al., 1995; Maj et al., 2003) , and decreases in dopamine transmission (Diana 177 et al., 1995) .
178
The observed correlation between anxiety-like behaviors and drug-seeking behaviors following 179 morphine conditioning in a three chamber apparatus ( Fig. 1F ) may suggest that animals seek the 180 drug-paired chamber as a consequence of negative reinforcement to alleviate aversive affective 181 states facilitated by opioid abstinence. Importantly, our injection regimen of morphine 10 mg/kg 182 once a day for 5 consecutive days does not induce signs of somatic withdrawal in mice including 183 jumping, wet dog shakes, teeth chattering, rearing, tremor, diarrhea, or mastication (Gallego et 184 al., 2010), coinciding with the lack of observed somatic withdrawal symptoms following a more 185 prolonged injection regimen of 5 daily morphine (10 mg/kg, i.p.) injections over 4 weeks 186 (Robinson and Kolb, 1999) . Although, more studies are required, it is plausible that specific 187 opioid dosing regimens may be implemented in a preclinical setting in order to separate opioid- Ketamine's effects on anxiety-like behaviors 193 Ketamine has recently been shown to be a potential effective treatment for anxiety disorders 194 (Glue et al., 2018; Shadli et al., 2018; Taylor et al., 2018) . In humans, ketamine displays a 195 biphasic dose effect on anxiety, with low doses decreasing anxiety and higher doses increasing anxiety (Jansen, 1989; Krystal et al., 1994) . Likewise, in rodents, ketamine induces anxiolytic-197 like behaviors (Engin et al., 2009; Zhang et al., 2015; Fraga et al., 2018) as well as anxiogenic-198 like phenotypes likely dependent upon the dose, temporal relationship between ketamine 199 injection and test onset, and rodent species (Silvestre et al., 1997; da Silva et al., 2010) . Here, we 200 demonstrate that in C57BL/6J mice, acute injection of ketamine at 10 mg/kg, i.p. 30 min prior to 201 testing is sufficient to block morphine-induced anxiety-like behaviors during a 24 h abstinence 202 time period (Fig. 2C) . Additionally, we find that ketamine significantly increases percent time in 203 the open arm of the elevated plus maze in mice conditioned with saline. This significant change 204 observed in saline conditioned animals suggests that ketamine, at the dose and temporal 205 relationship of ketamine injection and test onset, is sufficient to overcome baseline anxiety-like 206 behaviors in animals exposed to a novel environment (i.e., elevated plus maze). Together, these 207 findings suggest that ketamine is sufficient to reduce anxiety-like behaviors and morphine-208 seeking behaviors, further providing evidence that negative affective states drive morphine-209 induced place preference in the CPP model. performed 5 min or 15 min following ketamine administration appear to increase or decrease 238 locomotor activity, respectively (Filibeck and Castellano, 1980; Akillioglu et al., 2012) . Given 239 that the half-life of ketamine is ~13-25 min. in mice following i.p. administration (Maxwell et 240 al., 2006; Zanos et al., 2016; Ganguly et al., 2018) , it is possible that the locomotor effects 241 observed are due to ketamine action prior to metabolism, while the effects on negative affect are 242 potentially attributed to ketamine metabolites including hydroxynorketamine (Li et al., 243 2015; Zanos et al., 2016) . This hypothesis will need to be tested in future experiments.
244
Ketamine abolishes the correlation between anxiety-like behaviors and morphine-induced CPP 245 Based on our findings that ketamine elicited anxiolytic-like behaviors following an acute 246 injection, it is possible that the acute administration of ketamine was sufficient to prevent a 247 negative affective state during 24 h morphine abstinence, thus facilitating the lack of motivation 248 to seek a context paired with a drug reward (i.e., morphine-induced CPP). It is also plausible that 249 the block of morphine-induced CPP by ketamine may be mediated by its effects on cognition and 
Limitations to the use of ketamine as a treatment option for substance use disorders
Despite its therapeutic value, ketamine has undesirable side effects including drowsiness, 281 confusion, dizziness, and dissociative psychiatric side effects (Zarate et al., 2006; Diazgranados 282 et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013a) . Additionally, evidence suggests that 283 ketamine impairs cognition and memory (Harris et al., 1975; Ghoneim et al., 1985; Malhotra et 284 al., 1996; Newcomer et al., 1999; Pfenninger et al., 2002; Morgan et al., 2004; Honey et al., 285 2005; Mathew et al., 2010; Driesen et al., 2013) and may cause urological effects (Middela and 286 Pearce, 2011). A limitation of ketamine use as a treatment option for substance use disorders is 287 its abuse potential (Liu et al., 2016) . However, controlled studies in patients addressing the abuse 288 potential of low-dose ketamine are lacking and if the long-lasting ketamine effects shown here in 289 mice translate to human patients, the abuse liability can be mitigated by monthly physician-290 administered injections.
291

Conclusions 292
Here, we found that morphine conditioning in a three-compartment apparatus was sufficient to 293 elicit anxiety-like behaviors in mice, which were correlated with morphine-induced CPP.
294
Additionally, we provided evidence that acute ketamine pretreatment produces anxiolytic-like 295 behaviors and blocks morphine-induced CPP for a prolonged time period, suggesting that 296 ketamine is a potential option for attenuating negative reinforcement implicated in substance use 297 disorders. 
